apremilast / Generic mfg. - LARVOL DELTA

Apremilast and Adalimumab in Psoriatic Arthritis Patients (clinicaltrials.gov) - P=N/A | N=60 | Not yet recruiting | Sponsor: Tanta University

New trial • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

CNS Inflammatory Lesions in a Patient with Behçet’s Disease: A Case of Neuro-Behçet’s versus Behçet’s Disease with Multiple Sclerosis (ACTRIMS Forum 2026) - "She was started on apremilast, hydroxychloroquine, colchicine, and prednisone... This case highlights the challenge in determining a diagnosis of NBD versus BD with MS. Our patient’s CNS lesions appear more consistent with MS. However, certain factors raise the possibility of a diagnosis of NBD and overlap syndrome: she had a higher degree of disease activity than expected for MS while on high potency B-cell therapy, she had multi-system involvement related to BD as seen in her cardiac and gastroenterological manifestations, and she developed migrainous headaches prior to starting BD treatment which are a common presentation of NBD."

Clinical • CNS Disorders • Dermatology • Migraine • Multiple Sclerosis • Ocular Inflammation • Ophthalmology • Optic Neuritis • Rare Diseases • Uveitis • Vasculitis

Relative Efficacy of Immunomodulatory Monotherapies for Psoriasis of the Scalp: A Network Meta-Analysis Study. (PubMed, J Cosmet Dermatol) - "We are the first to provide comparative evidence on the efficacy of newly investigated agents such as deucravacitinib, tildrakizumab, roflumilast and icotrokinra. In general, the IL-17 inhibitors (bimekizumab, ixekizumab, secukinumab, brodalumab) and IL-23 inhibitors (icotrokinra, guselkumab, tildrakizumab) were effective depending upon the outcome and time-point being considered. At 16 weeks, for PSSI-100, ixekizumab 150 mg at weeks 0, 2, 4, 8, and 12 ranked highest; at 16 weeks, for Sc-PGA 0/1 bimekizumab 320 mg every 4 weeks ranked highest; at 8 weeks, for PSSI-100 ixekizumab 80 mg every 2 weeks ranked highest; at 8 weeks, for Sc-PGA 0/1 secukinumab 300 mg at weeks 1, 2, 3 and then every 4 weeks ranked highest. Small-molecule therapies (apremilast, deucravacitinib, roflumilast) improved scalp psoriasis modestly. Our work would guide the design of future studies and clinical decision-making."

Clinical • Journal • Retrospective data • Dermatology • Immunology • Psoriasis • IL17A • IL23A

Anti-CD19 Chimeric Antigen Receptor T-cell Therapy for Patients with Non-Hodgkin's Lymphoma and Concurrent Autoimmune Disease (TCT-ASTCT-CIBMTR 2026) - "9 pts (37.5%) remained on AID tx at apheresis, including hydroxychloroquine (HCQ) (n=4), sulfasalazine/mesalamine (n=2), and 1 each of prednisone, colestipol, sulfasalazine, and apremilast. In this study of CART for NHL we found no difference in clinical outcomes for pts with AID; we therefore propose that AID should not preclude the use of CART. The majority of pts were able to taper off AID tx prior to CART and HCQ was able to be safely continued throughout CART collection with no effect on efficacy. Our study also highlights the potential effect of CD19 directed CART on pt's AID given the majority of patients remained off AID tx for an extended time post-CART."

CAR T-Cell Therapy • Clinical • Ankylosing Spondylitis • B Cell Non-Hodgkin Lymphoma • CNS Disorders • Dermatology • Dermatomyositis • Gastroenterology • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lymphoma • Myasthenia Gravis • Myositis • Non-Hodgkin’s Lymphoma • Psoriasis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Plakoglobin phosphorylation at serine 665 is capable of stabilizing cadherin-mediated adhesion in keratinocytes. (PubMed, JCI Insight) - "Additionally, PG phosphorylated at S665 colocalized with desmoplakin and keratin filaments anchoring to desmosomes and increased cAMP-accelerated assembly of desmosomes. Taken together, phosphorylation of PG at S665 was crucial for protective effects of apremilast in pemphigus and for maintenance of DSG3 binding and keratin filament anchorage to desmosomes."

Journal • Immunology

Successful Long-Term Management of Psoriatic Arthritis With Apremilast Following Multiple Myeloma Diagnosis During Etanercept Therapy: A 20-Month Follow-up. (PubMed, Ann Pharmacother) - No abstract available

Journal • Hematological Malignancies • Immunology • Inflammatory Arthritis • Multiple Myeloma • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Two-Year Real-World Effectiveness of Deucravacitinib in Psoriasis: The Analysis Stratified by Prior Apremilast or Biologic Therapy. (PubMed, J Dermatol) - "Week 104 achieving PASI 75, PASI 90, PASI 100, and absolute PASI ≤ 1 were higher in biologic-naïve patients (84.6%, 57.7%, 15.4%, and 53.8%) than in biologic-experienced patients (25%, 25%, 0%, and 25%, respectively). Deucravacitinib reduced PASI and DLQI through 104 weeks in patients with psoriasis regardless of prior apremilast or biologic therapy, with lower sustainability of PASI 100 or absolute PASI ≤ 1 achievements in patients with prior apremilast or biologic treatment."

Journal • Real-world evidence • Dermatology • Immunology • Psoriasis • TYK2

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (clinicaltrials.gov) - P4 | N=10 | Not yet recruiting | Sponsor: University of California, San Francisco

New P4 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis

Product Sales Performance (PRNewswire) - "Repatha (evolocumab) sales increased 44% year-over-year to $870 million in the fourth quarter...UPLIZNA (inebilizumab-cdon) sales increased 131% year-over-year to $233 million in the fourth quarter and 73% for the full year, primarily driven by volume growth...TEZSPIRE (tezepelumab-ekko) sales increased 60% year-over-year to $474 million in the fourth quarter...Otezla (apremilast) sales were flat year-over-year at $625 million in the fourth quarter...Enbrel (etanercept) sales decreased 48% year-over-year to $532 million in the fourth quarter...PAVBLU (aflibercept-ayyh) generated $258 million of sales in the fourth quarter and $700 million for the full year....WEZLANA (ustekinumab-auub)/WEZENLA (ustekinumab) generated $44 million of sales in the fourth quarter and $273 million for the full year."

Sales • Ankylosing Spondylitis • Asthma • Cardiovascular • Chronic Rhinosinusitis With Nasal Polyps • Crohn's disease • Diabetic Macular Edema • Diabetic Retinopathy • Familial Hypercholesterolemia • Immunology • Myasthenia Gravis • Neuromyelitis Optica Spectrum Disorder • Psoriasis • Psoriatic Arthritis • Retinal Vein Occlusion • Rheumatoid Arthritis • Ulcerative Colitis • Wet Age-related Macular Degeneration

Challenges in managing primary toxoplasmosis in a patient with Behçet's disease receiving ustekinumab and apremilast and allergic to trimethoprim/sulfamethoxazole (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease • Rare Diseases

Systemic Treatment Strategies for Patients with Psoriasis and Psoriatic Arthritis in the Setting of ANA Positivity or Lupus Spectrum Disease: A Comprehensive Systematic Review. (PubMed, Int J Mol Sci) - "Mechanistic and translational studies-including ustekinumab and deucravacitinib SLE trial data and reports of IL-17 inhibitor-associated CLE-were reviewed separately to provide contextual interpretation...Apremilast, methotrexate, and mycophenolate mofetil remained reliable non-biologic systemic options...Personalized treatment strategies should integrate the relative dominance of psoriatic versus lupus disease, ANA/ENA profile, CLE subtype, and underlying mechanistic considerations. Prospective, biomarker-driven studies are needed to guide therapy in this increasingly recognized overlap population (PROSPERO registration: CRD420251241279)."

Journal • Review • Cutaneous Lupus Erythematosus • Dermatology • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Systemic Lupus Erythematosus • IL17A • IL23A • TYK2

PDE4 Inhibitor-Responsive Dermatoses: An Emerging Concept in Dermatology. (PubMed, J Clin Aesthet Dermatol) - "This suggests that PDE4 inhibitors may assume a similar complementary framework for treating "PDE4 inhibitor-responsive dermatoses." Certain formulations of PDE4 inhibitors (including apremilast, crisaborole, and roflumilast) have undergone rigorous investigation in clinical trials and demonstrated robust efficacy and safety in many dermatologic conditions, achieving United States Food and Drug Administration approval for atopic dermatitis, psoriasis, and seborrheic dermatitis. Herein, we summarize the clinical evidence supporting the emerging concept of "PDE4 inhibitor-responsive dermatoses" and propose that PDE4 inhibition offers an additional pathway to achieving desired clinical outcomes."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis • Seborrheic Dermatitis

Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results From the SPROUT Phase 3 Trial. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • P3 data • Dermatology • Immunology • Pediatrics • Psoriasis

Apremilast for Alcohol Use Disorder Treatment in Women and Men (clinicaltrials.gov) - P1 | N=10 | Active, not recruiting | Sponsor: Yale University | Trial completion date: Feb 2026 ➔ Aug 2026 | Trial primary completion date: Feb 2026 ➔ Aug 2026

Trial completion date • Trial primary completion date • Addiction (Opioid and Alcohol)

Dose-response Study of Apremilast in Women and Men With Alcohol Use Disorder (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Yale University | Initiation date: Nov 2025 ➔ Mar 2026

Trial initiation date • Addiction (Opioid and Alcohol)

Clinical Study on Secukinumab combined with Apremilast in the treatment of moderate-to-severe Plaque Psoriasis (ChiCTR) - P4 | N=90 | Not yet recruiting | Sponsor: Beijing Luhe Hospital, Capital Medical University; Beijing Luhe Hospital, Capital Medical University

New P4 trial • Dermatology • Immunology • Psoriasis

Trends in Inhibitors, Structural Modifications, and Structure-Function Relationships of Phosphodiesterase 4: A Review. (PubMed, Biomolecules) - "Although synthetic PDE4 inhibitors such as roflumilast and apremilast exhibit significant therapeutic efficacy, their clinical application is often limited by dose-dependent adverse effects. Their lower toxicity, favorable biocompatibility, and structural diversity enable fine-tuning of potency and selectivity through rational modification. Integrating structural insights derived from crystallographic and computational studies with the optimization of natural compounds offers a sustainable and effective strategy for the development of safer, isoform-selective PDE4-targeted therapies."

Journal • Review • Immune Modulation • Immunology • Inflammation

Apremilast for Recalcitrant Erythema Nodosum: A Case Series. (PubMed, Int J Dermatol) - No abstract available

Journal • Dermatology

APREMILAST-ASSOCIATED NON-ISCHEMIC CARDIOMYOPATHY IN A YOUNG MAN WITH PSORIASIS: EF RECOVERY AFTER DRUG WITHDRAWAL AND CRT-D (ACC 2026) - "Abstract is embargoed at this time."

Cardiomyopathy • Cardiovascular • Dermatology • Immunology • Psoriasis

Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis (clinicaltrials.gov) - P=N/A | N=36 | Not yet recruiting | Sponsor: Assiut University

New trial • Dermatology • Immunology • Psoriasis

Apremilast Drug Survival and Tolerability in Real-World Practice. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Real-world evidence • Dermatology • Immunology • Psoriasis

Erosive Oral Lichen Planus Treated With Upadacitinib Amid Systemic Psoriatic Therapy. (PubMed, Cureus) - "First-line therapies are topical corticosteroids or calcineurin inhibitors, while erosive OLP may require intralesional triamcinolone...Previous treatments, including prednisone, clobetasol gel, dexamethasone, chlorhexidine rinses, and mycophenolate, provided little relief. As her OLP remained unresponsive to treatment, her psoriasis also proved challenging, necessitating multiple therapeutic adjustments. She was started on apremilast for her PsO and PsA, which was ineffective. She transitioned to certolizumab pegol, which provided partial relief but led to recurrent infections. Bimekizumab was then initiated, clearing her PsO, but leaving her with persistent joint pain...Given the inflammatory pathway overlap between PsA and LP, JAK inhibition may mitigate the chronic inflammatory cascade that drives erosive OLP. Upadacitinib's efficacy in this case of refractory erosive OLP warrants further clinical studies to establish its therapeutic role."

Journal • Dermatology • Dermatopathology • Immunology • Infectious Disease • Inflammatory Arthritis • Lichen Planus • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • JAK3

Outcomes in Patients with Psoriasis Following Apremilast Treatment: Results from the German Psoriasis Registry PsoBest. (PubMed, Dermatol Ther (Heidelb)) - "Patients in routine care treated with apremilast in the German PsoBest registry experienced treatment benefits and improved skin, psoriasis severity, and quality of life. Safety was consistent with the established safety profile. Apremilast is safe and effective for treating moderate to severe psoriatic disease."

Journal • Cardiovascular • Dermatology • Immunology • Infectious Disease • Inflammatory Arthritis • Metabolic Disorders • Oncology • Pain • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital (clinicaltrials.gov) - P1 | N=106 | Recruiting | Sponsor: Syeda Sana Zaman

New P1 trial • Dermatology • Immunology • Psoriasis

Human Laboratory Study of Apremilast for Alcohol Use Disorder (clinicaltrials.gov) - P2 | N=100 | Not yet recruiting | Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)

New P2 trial • Addiction (Opioid and Alcohol)